منابع مشابه
The Antiiflammtory Activity of calcium-channel antagonists on chronic inflammation in rat
calcium mobilization is known to be an important factor in the activation of cells involved in inflammation,so,calcium-channel antagonists are be expected ti exhibit antiinflammatory activity.in the present study,we evaluateted the antiinflammatory effects of two calcium channel blockers,verapamil and nifedipine on adjuvant induced chronic in flammation in rat paw.sixty adult male rats were div...
متن کاملPCSK9 locus influence circulating PCSK9 levels
PCSK9 is a circulating protein, synthesized predominantly in the liver, involved in the regulation of the plasma low-density lipoprotein (LDL)–cholesterol concentration and associated with susceptibility to coronary heart disease (CHD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) shortens the half-life of the LDL-receptor (LDLR), a process independent of its catalytic activity. Human ...
متن کاملPCSK9 and Lipoprotein(a)
Proprotein convertase subtilisin kexin type 9 (PCSK9) has rapidly become a focus of intensive investigation worldwide because of its linkage to multiple clinically important facets of hepatic lipoprotein metabolism. To facilitate secretion and proper folding, the zymogen pro-PCSK9 must undergo autocatalytic cleavage. Once in the extracellular space, mature PCSK9 does not engage in proteolytic a...
متن کاملPCSK9 Inhibitors
Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular d...
متن کاملHealthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
BACKGROUND We measured plasma PCSK9 concentrations in healthy men with a PCSK9 (proprotein convertase subtilisin/kexin type 9) loss-of-function variant (p.R46L), in statin-treated patients with a clinical diagnosis of familial hypercholesterolemia (FH) and carrying a PCSK9 gain-of-function mutation (p.D374Y), and in statin-treated patients with FH due to different genetic causes. METHODS PCSK...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Atherosclerosis
سال: 2018
ISSN: 0021-9150
DOI: 10.1016/j.atherosclerosis.2017.10.022